pharmaceutical investing Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
pharmaceutical investing Allergan Aesthetics receives approval for Boey® , for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
pharmaceutical investing SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
pharmaceutical investing One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
pharmaceutical investing AbbVie Announces TEPKINLY® in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
pharmaceutical investing A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
pharmaceutical investing AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
pharmaceutical investing AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Severe Alopecia Areata
pharmaceutical investing AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
pharmaceutical investing The Aesthetics Giants Just Confirmed "Ozempic Face" Is Real - and a Newly Public Regenerative Player Wants to Compete for It
pharmaceutical investing BOTOX® Cosmetic Introduces The Confidence Collective's Entrepreneur Class of 2026
pharmaceutical investing Allergan Aesthetics receives approval for Boey® in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
pharmaceutical investing AbbVie Announces European Commission Approval of MAVIRET® for People with Acute Hepatitis C Virus Infection
Goldgroup Accelerates Growth Strategy Following Transformational Merger; Company Advances Multi-Asset Drill Programs, Mine Development and Expansion Plans
Syntholene Energy Corp. Upsizes Private Placement to $2.0 Million and Announces Closing of First Tranche
